Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Other Non-Current Assets (2022 - 2025)

Orchestra BioMed Holdings (OBIO) has disclosed Other Non-Current Assets for 4 consecutive years, with $1.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Other Non-Current Assets fell 0.54% to $1.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $1.3 million, a 0.54% decrease, with the full-year FY2024 number at $1.0 million, up 32.64% from a year prior.
  • Other Non-Current Assets was $1.3 million for Q3 2025 at Orchestra BioMed Holdings, up from $1.3 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $4.7 million in Q4 2022 to a low of $421000.0 in Q1 2023.
  • A 4-year average of $1.2 million and a median of $957000.0 in 2024 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: plummeted 83.68% in 2023, then surged 115.73% in 2024.
  • Orchestra BioMed Holdings' Other Non-Current Assets stood at $4.7 million in 2022, then tumbled by 83.68% to $769000.0 in 2023, then skyrocketed by 32.64% to $1.0 million in 2024, then rose by 27.06% to $1.3 million in 2025.
  • Per Business Quant, the three most recent readings for OBIO's Other Non-Current Assets are $1.3 million (Q3 2025), $1.3 million (Q2 2025), and $1.3 million (Q1 2025).